Pulmonary Fibrosis Biomarkers Market Analysis

Based on test type, the market is segmented into blood test, pulmonary function test, imaging test, lung biopsy, and other test types. The imaging test segment held the market size of USD 1.7 billion in 2023.

• Patients with pulmonary fibrosis undergo periodic imaging tests to monitor disease progression and response to treatment. The findings are correlated with biomarker data to enhance understanding and accuracy in disease assessment. Consequently, the synergy between imaging and biomarkers drives the use of both modalities.
  
• Moreover, the advanced imaging tool, such as high-resolution computed tomography (HRCT) scan is the gold standard for diagnosing pulmonary fibrosis. It provides detailed images of lung structures, allowing for the identification of characteristic patterns of fibrosis.
  
• Additionally, imaging tests complement biomarker analysis, providing a comprehensive view of disease status. Thus, their role in diagnosis, disease monitoring, treatment planning, and research makes them essential tools in the management of pulmonary fibrosis.
  

Based on indication, the pulmonary fibrosis biomarkers market is segmented into idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis interstitial lung disease (RA-ILD), drug-induced pulmonary fibrosis, COVID-19-related pulmonary fibrosis, pneumoconiosis, sarcoidosis, and other indications. The idiopathic pulmonary fibrosis (IPF) segment is expected reach a market size of USD 2.1 billion by 2032.

• Idiopathic pulmonary fibrosis (IPF) is the most common and well-known form of idiopathic interstitial pneumonia, accounting for a significant proportion of interstitial lung diseases. For instance, according to the National Library of Medicine, IPF has an estimated prevalence of 13 to 20 per 1,00,000 people worldwide. About 1,00,000 people are affected in the U.S., and 30,000 to 40,000 new cases are diagnosed each year.
  
• Biomarkers such as MMP-7, SP-A, and cytokines IL-6, TGF-β) are associated with disease severity and prognosis. Data from them provide insights into disease activity and treatment response for idiopathic pulmonary fibrosis.
  

Based on end-user, the pulmonary fibrosis biomarkers market is classified into hospitals, specialty clinics, diagnostic laboratories, research & academic institutes, and other end-users. The hospitals segment held a market share of 33.4% in the year 2023.

• Hospitals play a central role in managing pulmonary fibrosis patients. As, biomarkers are used for monitoring disease progression, treatment response, and overall patient care under one roof.
  
• Additionally, many hospitals have specialized laboratories equipped for biomarker testing, with pulmonologists, radiologists, and pathologists working together. Consequently, biomarkers are utilized by these teams for collaborative decision-making in patient management.
  
• For instance, according to the National Library of Medicine, in 2021, in-hospital mortality rates among patients with IPF have been reported to be approximately 13% to 15%. Thus, hospitals with specialized pulmonary fibrosis programs and experienced care teams helps to reduce the mortality rates, thereby influencing the market growth.
  

North America pulmonary fibrosis biomarkers market accounted for USD 1.7 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.

• The significant market share is correlated to a highly advanced healthcare infrastructure with well-established hospitals, research institutions, and diagnostic laboratories. This infrastructure enables the widespread adoption of biomarker testing for pulmonary fibrosis.
  
• North America has a relatively high prevalence of pulmonary fibrosis, a chronic and progressive lung disease. For instance, according to the American Lung Association, in 2023, around 33.8 million adults were being diagnosed with chronic lung disease.
  
• There is a growing awareness of pulmonary fibrosis among healthcare professionals and the general population in region. Early diagnosis and monitoring of the disease are crucial for better patient outcomes, leading to increased adoption of biomarker testing.